Non-Steroidal Androgen Receptor Antagonists for Advanced Prostate Cancer Therapy
This invention features a new class of non-steroidal compounds designed to act as highly potent androgen receptor antagonists. They offer a powerful therapeutic strategy to inhibit prostate cancer cell growth, specifically targeting strains resistant to current standard-of-care treatments.
Description
The technology encompasses a unique series of non-steroidal analogs structured to bind effectively to the androgen receptor (AR) and suppress its biological activity. These molecules utilize specialized chemical frameworks to optimize their binding affinity and metabolic stability. By altering the core architecture compared to conventional treatments, these compounds avoid the molecular vulnerabilities that typically allow mutating cancer cells to develop resistance. In vitro screening demonstrates that these novel agents significantly suppress AR-mediated transcription and cell proliferation in both standard and enzalutamide-resistant prostate cancer cell lines. They exhibit nanomolar potency (IC50 values) in reducing the expression of Prostate-Specific Antigen (PSA) and driving down tumor cell viability. Furthermore, structural modifications, such as evaluating specific enantiomeric forms, have allowed the fine-tuning of their pharmacokinetic profile, balancing strong therapeutic efficacy with optimal metabolic clearance.Applications
- Advanced Oncology Therapeutics: Development of next-generation oral therapeutics specifically for metastatic castration-resistant prostate cancer (mCRPC).- Combination Drug Regimens: Implementation alongside existing standards of care like abiraterone or enzalutamide to maximize tumor suppression.
- Androgen-Driven Disorder Treatments: Expansion into clinical therapies for other conditions mediated by hyperactive androgen receptors.
- Diagnostic and Research Assays: Employment as highly selective control reagents or chemical probes in academic and corporate AR signaling research.
Advantages
- Overcomes Treatment Resistance: Demonstrates robust efficacy against enzalutamide-resistant prostate cancer cell models.- High Anti-Androgenic Potency: Achieves significant suppression of androgen receptor activity and PSA levels at nanomolar concentrations.
- Non-Steroidal Advantage: Minimizes the broad off-target metabolic or hormonal side effects frequently associated with traditional steroidal agents.
- Optimized Metabolic Stability: Engineered with structural modifications that improve half-life and resistance to rapid enzymatic breakdown.
- Flexible Combinatorial Potential: Fully compatible with existing therapeutic regimens, such as androgen deprivation therapy (ADT) or modern anti-androgens.